Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.21.2
Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2021
Dec. 31, 2020
Current assets    
Cash and cash equivalents $ 9,682,000 $ 5,297,000
Short-term investments 26,031,000 0
Prepaid expenses and other current assets 85,000 364,000
Total Current Assets 35,798,000 5,661,000
Current liabilities    
Accounts payable 2,802,000 2,243,000
Accrued expenses 749,000 1,296,000
Accrued interest 0 4,838,000
Convertible notes payable (net of discount of $4,519,000 at December 31, 2020) 0 26,303,000
Line of Credit 31,000 31,000
Derivative liability 340,000 383,000
Total current liabilities 3,922,000 35,094,000
Stockholders' Equity (Deficit):    
Common stock, par value $0.001, 2,000,000,000 shares authorized, 30,508,260 and 5,218,122 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively 30,000 5,000
Common stock issuable, 1,004,000 shares at September 30, 2021 3,416,000 0
Additional paid in capital 663,991,000 566,356,000
Accumulated deficit (635,393,000) (595,628,000)
Non-Controlling Interest (169,000) (169,000)
Total stockholders' equity (deficit) 31,876,000 (29,433,000)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) 35,798,000 5,661,000
Series J    
Stockholders' Equity (Deficit):    
Convertible Preferred stock 0 2,000
Series C    
Stockholders' Equity (Deficit):    
Convertible Preferred stock 1,000 1,000
Series K    
Stockholders' Equity (Deficit):    
Convertible Preferred stock $ 0 $ 0